Brukinsa (zanubrutinib) Approved in the U.S. for Chronic Lymphocytic Leukemia

BASEL, Switzerland& BEIJING& CAMBRIDGE, Mass. -- January 19, 2023 --(BUSINESS WIRE)-- BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news